Old Web
English
Sign In
Acemap
>
authorDetail
>
Ligia Chialda
Ligia Chialda
Northwick Park Hospital
Medicine
Pharmacology
Tolerability
Pharmacokinetics
5-lipoxygenase-activating protein
4
Papers
76
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes
2019
Nature Communications
Li-Ming Gan
Maria Lagerström-Fermér
Leif Carlsson
Cecilia Arfvidsson
Ann-Charlotte Egnell
Anna Rudvik
Magnus Kjaer
Anna Collén
James D. Thompson
John Joyal
Ligia Chialda
Thomas Koernicke
Rainard Fuhr
Kenneth R. Chien
Regina Fritsche-Danielson
Show All
Source
Cite
Save
Citations (56)
Clinical safety, tolerability, pharmacokinetics and effects on urinary electrolyte excretion of AZD9977, a novel, selective mineralocorticoid receptor modulator
2018
British Journal of Clinical Pharmacology
Fredrik Erlandsson
Muna Albayaty
Ligia Chialda
Hans Ericsson
Carl Amilon
Karin Nelander
Rasmus Jansson-Löfmark
Linda Wernevik
Magnus Kjaer
Krister Bamberg
Judith Hartleib-Geschwindner
Show All
Source
Cite
Save
Citations (7)
Initial Clinical Experience with AZD5718, a Novel Once Daily Oral 5‐Lipoxygenase Activating Protein Inhibitor
2018
Clinical and Translational Science
Hans Ericsson
Karin Nelander
Maria Lagerström-Fermér
Clare A. Balendran
Maria Bhat
Ligia Chialda
Li-Ming Gan
Maria Heijer
Magnus Kjaer
John Lambert
Eva-Lotte Lindstedt
Gun-Britt Forsberg
Carl Whatling
Stanko Skrtic
Show All
Source
Cite
Save
Citations (13)
P2319Initial clinical experience with AZD5718, a novel once daily oral 5-lipoxygenase activating protein (FLAP) inhibitor, intended for patients with coronary artery disease
2017
European Heart Journal
Stanko Skrtic
Clare A. Balendran
M Bhat
Ligia Chialda
Hans Ericsson
Li-Ming Gan
Maria Heijer
Magnus Kjaer
Maria Lagerström-Fermér
J. Lambert
E.-L. Lindstedt
Karin Nelander
Carl Whatling
Show All
Source
Cite
Save
Citations (0)
1
map